Research Article
Skeletal Manifestations, Bone Pain, and BMD Changes in Albanian Type 1 Gaucher Patients Treated with Taliglucerase Alfa
Table 1
General data of our patients.
| Number of patients at baseline | 24 |
| Number of patients at the end of study | 20 |
| Gender (F-M) | 7/13 (end of the study) |
| Genotype | 19/p.Asn409Ser:p.His294Gln/pAsp448His | 2/p.Asn409Ser:pArg 502His | 1/p.Asn409Ser:pSer146Leu | 1/p.Asn409Ser:p/Arg86 | 1/p. Asn409Ser: p/LeuProfs4: Arg87Trp |
| Age at baseline | 28.7 ± 16.5 (min age: 7 y, max age: 72 y) |
| Children (under 18 y)/adults | 8/16 |
| Naïve patients | 8 patients |
| Switched patients | 12 patients switched at baseline (imiglucerase to taliglucerase) | 2 patients switched during FU (taliglucerase to velaglucerase) |
| Splenectomized | 2 |
|
|